NASDAQ: ONTX was downgraded by  Zacks Research  from a “buy” ranking to a “hold” rating in a research note released to investors on Thursday, reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on uncovering as well as developing small molecule medication prospects to deal with cancer cells. The Company‘s products under various phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research analysts also lately talked about the firm. Noble Financial reissued a “purchase” rating and provided a $11.00 rate goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and set a “acquire” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day relocating ordinary cost of $2.90 as well as a two-hundred day moving typical cost of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, topping analysts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as an adverse net margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, contrasted to the consensus price quote of $0.06 million. Throughout the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.

A number of hedge funds have actually recently bought and sold shares of ONTX. GSA Resources Partners LLP purchased a new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Funding Monitoring LP acquired a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and various other institutional investors own 13.36% of the business’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which takes part in the recognition and advancement of oncology therapeutics. It concentrates on finding as well as developing small molecule medicine candidates to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more information about research offerings from Zacks Investment Research, check out

This instantaneous information alert was created by narrative scientific research innovation as well as economic data from Market in order to supply visitors with the fastest as well as most exact coverage. This story was evaluated by Market’s editorial team prior to publication. 



Prior to you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market tracks Wall Street’s premier and also finest performing research analysts and the stocks they advise to their customers on a daily basis. Market has determined the five stocks that top analysts are silently murmuring to their customers to get currently prior to the more comprehensive market catches on … and also Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” score among experts, top-rated experts think these five stocks are better purchases.